How does your treatment approach vary in patients with HR+/HER2- breast cancer presenting with CNS metastases?
While rare, these patients were excluded from all frontline CDK4/6 inhibitor trials. Is there any data on the efficacy of ribociclib in the CNS or ability to cross BBB as there is for abemaciclib?
Community PollStarted
What is your preferred CDK 4/6 inhibitor for metastatic breast cancer to CNS?
71 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet Member
Medical Oncology · Memorial Sloan Kettering Cancer Center
Answered on
There are preclinical studies published about ribociclib entering the CNS (Patel et al., PMID 31079218), as well as some clinical studies in non-breast tumors such as meningiomas (Sanai et al., ESMO 2019). However, I am not aware of any published studies in ribociclib analogous to the Phase 2 trial ...
Join for free or sign in to see the full answer
Mednet Member
Medical Oncology · UCLA
Answered on
Besides abemaciclib, ribociclib can cross BBB as well and there is some data to support this, albeit limited to case reports and real-world setting:
Join for free or sign in to see the full answer